Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Bedossa

Showing results (201-210 of 267) with videos related to

Pageof 27
Sort By:
Gastroenterology|January 1, 2008
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosisRami Moucari, Tarik Asselah, Dominique Cazals-Hatem, et al.
Alimentary Pharmacology & Therapeutics|October 3, 2023
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitisStephen A Harrison, Vlad Ratziu, Quentin M Anstee, et al.
The American Journal of Pathology|June 7, 2011
Changes in autophagic response in patients with chronic hepatitis C virus infectionPierre-Emmanuel Rautou, Dominique Cazals-Hatem, Gérard Feldmann, et al.
Journal of Hepatology|January 18, 2011
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patientsEsther Zimmermann, Rodolphe Anty, Joan Tordjman, et al.
Contemporary Clinical Trials|December 28, 2019
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study designQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Hepatology (Baltimore, Md.)|November 1, 2020
Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of SteatohepatitisBubu A Banini, Divya P Kumar, Sophie Cazanave, et al.
Hepatology (Baltimore, Md.)|January 26, 2017
A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitisJulien Bissonnette, José Altamirano, Cécile Devue, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver diseaseMarie Boyle, Dina Tiniakos, Jorn M Schattenberg, et al.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.
Journal of Hepatology|March 22, 2021
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohortStephen A Harrison, Samer Gawrieh, Katharine Roberts, et al.
Pageof 27

Showing results (201-210 of 267) with videos related to

Sort By:
Pageof 27
Gastroenterology|January 1, 2008
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosisRami Moucari, Tarik Asselah, Dominique Cazals-Hatem, et al.
Alimentary Pharmacology & Therapeutics|October 3, 2023
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitisStephen A Harrison, Vlad Ratziu, Quentin M Anstee, et al.
The American Journal of Pathology|June 7, 2011
Changes in autophagic response in patients with chronic hepatitis C virus infectionPierre-Emmanuel Rautou, Dominique Cazals-Hatem, Gérard Feldmann, et al.
Journal of Hepatology|January 18, 2011
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patientsEsther Zimmermann, Rodolphe Anty, Joan Tordjman, et al.
Contemporary Clinical Trials|December 28, 2019
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study designQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Hepatology (Baltimore, Md.)|November 1, 2020
Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of SteatohepatitisBubu A Banini, Divya P Kumar, Sophie Cazanave, et al.
Hepatology (Baltimore, Md.)|January 26, 2017
A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitisJulien Bissonnette, José Altamirano, Cécile Devue, et al.
JHEP Reports : Innovation in Hepatology|February 11, 2020
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver diseaseMarie Boyle, Dina Tiniakos, Jorn M Schattenberg, et al.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.
Journal of Hepatology|March 22, 2021
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohortStephen A Harrison, Samer Gawrieh, Katharine Roberts, et al.
Pageof 27